[go: up one dir, main page]

MX2007003104A - Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a. - Google Patents

Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.

Info

Publication number
MX2007003104A
MX2007003104A MX2007003104A MX2007003104A MX2007003104A MX 2007003104 A MX2007003104 A MX 2007003104A MX 2007003104 A MX2007003104 A MX 2007003104A MX 2007003104 A MX2007003104 A MX 2007003104A MX 2007003104 A MX2007003104 A MX 2007003104A
Authority
MX
Mexico
Prior art keywords
aurora
kinase inhibitors
phthalazinone derivatives
novel phthalazinone
novel
Prior art date
Application number
MX2007003104A
Other languages
English (en)
Inventor
Stefan Scheiblich
Wolfgang Von Der Saal
Guy Georges
Stefan Weigand
Bernhard Goller
Matthias Rueth
Edward Boyd
Frederick Brookfield
Sabine Huensch
Petra Rueger
Christine Schuell
Justine Warne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2007003104A publication Critical patent/MX2007003104A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Son objetos de la presente invencion los compuestos de la formula (I) sus sales, formas enantiomericas, diaestereoisomeros y racematos farmaceuticamente aceptables, la obtencion de los compuestos recien mencionados, los medicamentos que los contienen y su fabricacion, asi como el uso de los compuestos recien mencionados para el control o prevencion de enfermedades, tales como el cancer.
MX2007003104A 2004-09-24 2005-09-23 Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a. MX2007003104A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04022755 2004-09-24
PCT/EP2005/010311 WO2006032518A1 (en) 2004-09-24 2005-09-23 Novel phthalazinone derivatives, as aurora-a kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2007003104A true MX2007003104A (es) 2007-06-07

Family

ID=34926696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003104A MX2007003104A (es) 2004-09-24 2005-09-23 Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.

Country Status (16)

Country Link
US (1) US7226923B2 (es)
EP (1) EP1794148B1 (es)
JP (1) JP2008514564A (es)
KR (1) KR100907202B1 (es)
CN (1) CN101027290B (es)
AR (1) AR050948A1 (es)
AT (1) ATE428708T1 (es)
AU (1) AU2005287458A1 (es)
BR (1) BRPI0515885A (es)
CA (1) CA2580198A1 (es)
DE (1) DE602005013985D1 (es)
ES (1) ES2323885T3 (es)
MX (1) MX2007003104A (es)
RU (1) RU2397166C2 (es)
TW (1) TW200624431A (es)
WO (1) WO2006032518A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2645583A1 (en) * 2006-03-20 2007-09-27 F. Hoffman-La Roche Ag Methods of inhibiting btk and syk protein kinases
WO2007107298A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
US9162953B2 (en) * 2006-07-05 2015-10-20 Centre Nationale De Recherche Scientifique Iron-copper co-catalyzed process for carbon-carbon or carbon-heteroatom bonding
GB0619342D0 (en) * 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
DE102008000872A1 (de) 2007-04-11 2008-11-13 Basf Se Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
BR112013028886A2 (pt) * 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
WO2015095284A1 (en) 2013-12-18 2015-06-25 Monsanto Technology Llc Processes for the diazotization of 2,5-dichloroanilines
WO2016130460A2 (en) * 2015-02-09 2016-08-18 The Johns Hopkins University Phthalazinone pyrazole derivatives for treating retinal degenerative disease
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
RU2674761C2 (ru) * 2016-12-21 2018-12-13 федеральное государственное бюджетное образовательное учреждение высшего образования "Тольяттинский государственный университет" Способ получения анилина и катализатор для него
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
CN108250150B (zh) * 2018-03-15 2020-12-29 兰州大学 一种肽嗪酮化合物及其制备方法与应用
CN111039940B (zh) * 2019-12-31 2022-10-21 北京鑫开元医药科技有限公司 一种Aurora A激酶抑制剂、制备方法、药物组合物及其用途
CN113773263B (zh) * 2020-06-10 2023-09-19 兰州大学 一种4-胺取代酞嗪酮极光激酶b抑制剂及其制备与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
JP2890267B2 (ja) 1994-02-23 1999-05-10 ファイザー インク． ４−ヘテロサイクリル−置換キナゾリン誘導体、その調製法および抗癌剤としてのその使用法
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
CA2239692C (en) 1995-12-18 2008-12-16 Sugen, Inc. Diagnosis and treatment of aur-1 and/or aur-2 related disorders
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6180629B1 (en) * 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
CZ20021009A3 (cs) 1999-09-21 2002-06-12 Astrazeneca Ab Deriváty chinazolinu, způsob jejich přípravy a jejich pouľití jako léčiv
HK1046688A1 (zh) 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1294709A2 (en) 2000-01-28 2003-03-26 AstraZeneca AB Quinoline derivatives and their use as aurora 2 kinase inhibitors
CN1240688C (zh) 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
KR100957516B1 (ko) 2001-08-15 2010-05-14 이코스 코포레이션 2ｈ-프탈라진-1-온 및 이것의 사용 방법
NZ533440A (en) 2001-12-24 2006-08-31 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
PL371587A1 (en) * 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
ATE365733T1 (de) 2002-03-15 2007-07-15 Vertex Pharma Zusammensetzungen brauchbar als protein-kinase- inhibitoren
EP1485100B1 (en) 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
EP1485380B1 (en) 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
WO2003078426A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases

Also Published As

Publication number Publication date
AR050948A1 (es) 2006-12-06
US20060089359A1 (en) 2006-04-27
EP1794148A1 (en) 2007-06-13
AU2005287458A1 (en) 2006-03-30
EP1794148B1 (en) 2009-04-15
TW200624431A (en) 2006-07-16
KR20070046193A (ko) 2007-05-02
US7226923B2 (en) 2007-06-05
DE602005013985D1 (de) 2009-05-28
WO2006032518A1 (en) 2006-03-30
RU2007115161A (ru) 2008-11-10
ES2323885T3 (es) 2009-07-27
CN101027290B (zh) 2010-05-12
JP2008514564A (ja) 2008-05-08
BRPI0515885A (pt) 2008-08-12
ATE428708T1 (de) 2009-05-15
CA2580198A1 (en) 2006-03-30
RU2397166C2 (ru) 2010-08-20
CN101027290A (zh) 2007-08-29
KR100907202B1 (ko) 2009-07-10

Similar Documents

Publication Publication Date Title
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
TW200635923A (en) Tricyclic heterocycles, their manufacture and use as pharmaceutical agents
TW200730502A (en) Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
WO2006066913A3 (en) Benzamide substituted imidazo- and pyrolo-pyridines as protein kinase inhibitors
ATE500245T1 (de) Pyridonamidderivate als fokale adhäsionskinase (fak)-inhibitoren und ihre verwendung zur behandlung von krebs
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
TW200512205A (en) Quinazoline derivatives
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
WO2006066914A3 (en) Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
GB0308201D0 (en) Novel compounds
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
TW200531688A (en) Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
MX2008011769A (es) Derivados de ftalazinona pirazol, su fabricacion y uso como agentes farmaceuticos.
IL198630A0 (en) Pyrimidyl derivatives as protein kinase inhibitors
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
MXPA05011671A (es) Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos.
TW200602329A (en) Novel diazine derivatives, their manufacture and use as pharmaceutical agents
MX2007003463A (es) Triciclos, su elaboracion y su uso como agentes farmaceuticos.
TW200720239A (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
FG Grant or registration